Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
Sponsor: American Heart Association
Listed as NCT02526485, this observational or N/A phase trial focuses on Heparin-induced Thrombocytopenia and remains completed. Sponsored by American Heart Association, it has been updated 14 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 9 earlier versions
-
Mar 2020 — Nov 2020 [monthly]
Completed
Status: Recruiting → Completed
-
Nov 2019 — Mar 2020 [monthly]
Recruiting
-
Oct 2018 — Nov 2019 [monthly]
Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Recruiting NA
-
Aug 2017 — Oct 2017 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American Heart Association
- Vanderbilt University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .